Molecular Partners AG
SIX:MOLN
Molecular Partners AG
SIX:MOLN
Price:
3.79
CHF
-1.81%
Market Closed
Market Cap:
CHf153m
Molecular Partners AG
EPS (Diluted)
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Molecular Partners AG
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
EPS (Diluted)
-CHf1
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
EPS (Diluted)
-$6
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-26%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
EPS (Diluted)
CHf2
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
53%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
EPS (Diluted)
-CHf1
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
MOLN Intrinsic Value
HIDDEN
See Also
What is Molecular Partners AG's EPS (Diluted)?
EPS (Diluted)
-1.7
CHF
-1.7
CHF
Based on the financial report for Sep 30, 2025, Molecular Partners AG's EPS (Diluted) amounts to -1.7 CHF.
What is Molecular Partners AG's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
24%
24%
Over the last year, the EPS (Diluted) growth was 24%.
